Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 5Brain Neoplasms 2Neuroblastoma 1Meningioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1

Interventions

Temozolomide 163Radiosurgery 129Radiotherapy 107Bevacizumab 98Magnetic Resonance Spectroscopy 75Carboplatin 48Surgical Procedures, Operative 35pembrolizumab 34Radiation 34Etoposide 34Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Lomustine 26Trastuzumab 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × apatinib × CNS × Clear all
NCT03801200 2022-02-08

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

Hubei Cancer Hospital

Phase 2 Unknown
90 enrolled
CNS

Brain Neoplasms

NCT03356600 2017-12-11

Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer

Shanxi Province Cancer Hospital

Phase 2 Unknown
44 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡